Table 1.
Unit costs used in the calculation of healthcare costs and productivity losses.
| Year | Value in 2018 SEK | Value in 2018 Eurosa | Source | |
|---|---|---|---|---|
| Average inpatient and outpatient cost per 1.0 DRG | 2006 | 50,973 kr | 4969 € | Swedish Association of Local Authorities and Regions [Sveriges Kommuner och Landsting], KPP Somatik vård 20 |
| 2007 | 50,224 kr | 4896 € | ||
| 2008 | 51,388 kr | 5009 € | ||
| 2009 | 51,785 kr | 5048 € | ||
| 2010 | 50,457 kr | 4919 € | ||
| 2011 | 50,286 kr | 4902 € | ||
| 2012 | 49,820 kr | 4857 € | ||
| 2013 | 51,468 kr | 5017 € | ||
| 2014 | 53,388 kr | 5204 € | ||
| 2015 | 55,807 kr | 5440 € | ||
| 2016 | 57,334 kr | 5589 € | ||
| Co-payment for hospital stay (cost per day of stay) | 2018 | 100 kr | 10 € | Assume 100 SEK per day, as this is the case for the majority of the regions in Sweden (including Stockholm). 21 The max co-payment amount for inpatient care was set to 1500 SEK per year (assumption for whole Sweden, based on information from the region Västra Götaland) 22 |
| Co-payment for visit in specialized care (cost per visit) | 2018 | 273 kr | 27 € | Swedish Association of Local Authorities and Regions. The max co-payment amount for outpatient care was set to 1100 SEK per year. Only one region in Sweden has a max co-payment less than 1100 SEK; so it was assumed 1100 SEK for the entire country. Swedish Association of Local Authorities and Regions 21 |
| Cost per month for natalizumab | 2018 | 15,839 kr | 1544 € | Treatment with natalizumab is every 4th week (i.e. one per month); 23 therefore, the cost per month of natalizumab was assumed to be the price for one dose of natalizumab (pharmacy's retail price), 23 excluding the cost of administration. The latter is partially captured in this study as an outpatient visit to the hospital, excluding infusion visits with a nurse, which are unfortunately not in the NPR. |
| Cost per month for rituximab | 2018 | 2022 kr | 197 € | Rituximab is used off-label in the treatment of MS; therefore, the exact treatment dosing was not available in the Swedish guidelines for MS treatment. A recent published study in Sweden regarding the use of rituximab for PwMS indicated that the drug dose is 500mg to 1000mg per treatment regime (here we assumed the mean, i.e 750mg per treatment regime), and the mean treatment interval for RRMS PwMS was 7.2 months per year. 24 The cost per month was then assumed to be 1.5 times the pharmacy's retail price per 500mg of rituximab injection, which was taken from FASS (9703.61 SEK), 25 divided with the frequency of treatment in months (frequency: every 7.2 months). 24 |
| Monthly salary including employer contributions | 2006 | 40,930 kr | 4248 € | The average age-adjusted monthly wage (2018 values) for all employment types was retrieved. 26 It was multiplied with the annual employer contributions, available from the Swedish Tax Authority. 27 The final salary was then inflated to 2018 prices using annual Harmonized Indices of Consumer Prices [HICP] for healthcare available from Eurostat. 28 |
| 2007 | 41,049 kr | 4260 € | ||
| 2008 | 40,042 kr | 4156 € | ||
| 2009 | 44,583 kr | 4627 € | ||
| 2010 | 44,080 kr | 4575 € | ||
| 2011 | 44,730 kr | 4642 € | ||
| 2012 | 44,748 kr | 4644 € | ||
| 2013 | 45,051 kr | 4676 € | ||
| 2014 | 46,120 kr | 4787 € | ||
| 2015 | 50,300 kr | 5221 € | ||
| 2016 | 48,146 kr | 4997 € |
a
The annual exchange rate for 2018 from SEK to Euros that was used was 10.2583. Source: Eurostat, Annual Exchange Rates Euro/ECU.